Disease Landscape and Forecast Insights

Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these…

Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizable portion of the Chinese population every year. With the introduction of proteasome…

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

Clarivate Epidemiology’s coverage of alopecia areata (AA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic neuroinflammatory disorder that can lead to blindness and paralysis. Most patients have a relapsing form of the disease, leading to…

The type 2 diabetes (T2D) therapy market will expand over the first half of the 2020-2030 forecast period. This increase will partly be fueled by a rich pipeline of novel agents, including emerging…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…

With an increasing prevalence due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will…

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis that most often affects the arteries in the lower extremities. This condition is a major marker for more-…

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in…

A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next 10 years and challenge the dominance of the TNF inhibitors,…